A randomized double-blind study using CaNa2EDTA, a phospholipase A2 inhibitor, in the management of human acute pancreatitis

In a randomized double-blind study the effect of CaNa2EDTA, a phospholipase A2 inhibitor, was tested as a treatment for acute pancreatitis. CaNa2EDTA was infused intravenously during the first 2 days after admission to hospital, in addition to normal conservative treatment. CaNa2EDTA decreased the s...

Full description

Saved in:

Bibliographic Details
Published in:	Scandinavian journal of gastroenterology Vol. 20; no. 1; p. 5
Main Authors:	Tykkä, H T, Vaittinen, E J, Mahlberg, K L, Railo, J E, Pantzar, P J, Sarna, S, Tallberg, T
Format:	Journal Article
Language:	English
Published:	England 01-01-1985
Subjects:	Acute Disease Annexins Calcium-Binding Proteins Clinical Trials as Topic Double-Blind Method Edetic Acid - therapeutic use Female Glycoproteins - therapeutic use Humans Male Middle Aged Pancreatitis - drug therapy Pancreatitis - metabolism Phospholipases - antagonists & inhibitors Phospholipases A - antagonists & inhibitors Phospholipases A2 Random Allocation
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In a randomized double-blind study the effect of CaNa2EDTA, a phospholipase A2 inhibitor, was tested as a treatment for acute pancreatitis. CaNa2EDTA was infused intravenously during the first 2 days after admission to hospital, in addition to normal conservative treatment. CaNa2EDTA decreased the serum phospholipase A2 activity and appeared to promote recovery from the illness. To what extent the inhibition of serum phospholipase activity may prevent the progress of severe haemorrhagic pancreatitis or diminish mortality and morbidity in acute pancreatitis should be investigated in further studies.
ISSN:	0036-5521
DOI:	10.3109/00365528509089625